薯蕷丸加減方治療變應(yīng)性鼻炎大鼠的實驗研究
發(fā)布時間：2019-06-20 23:25
【摘要】：目的：復(fù)制變應(yīng)性鼻炎(AR)大鼠模型，觀察薯蕷丸加減方對AR大鼠行為學(xué)指標(biāo)、血清總IgE和IL-4含量值、鼻黏膜病理形態(tài)及水通道蛋白5(AQP5)表達的影響，初步探討該方治療AR的作用機理，為該方更好地運用于臨床提供實驗理論依據(jù)。 方法：SPF級SD大鼠70只，雄性，隨機分為：正常對照組、模型組、辛芩顆粒組、通竅鼻炎片組及薯蕷丸加減方高、中、低劑量組，每組10只。除正常對照組外，各組采用卵白蛋白(OVA)復(fù)制AR大鼠模型。造模成功后，模型組和正常對照組給予口飼生理鹽水(1ml/0.1kg·d)。高、中、低劑量組分別給予薯蕷丸加減方水煎劑(32、16、8g/kg·d)灌胃，陽性對照組采用辛芩顆粒(5g/kg·d)、通竅鼻炎片(1.8g/kg·d)灌胃。均給藥14d后，麻醉大鼠，抽取腹主動脈血，用酶聯(lián)免疫吸附測定法(ELISA)檢測血清總IgE、IL-4含量值；處死大鼠摘取鼻黏膜，，HE染色觀察；免疫組化SABC法檢測鼻黏膜AQP5表達。 結(jié)果：造模后各組行為學(xué)積分均高于正常對照組(P＜0.01)；各組間差異不明顯(P＞0.05)；灌胃14d后，各治療組行為學(xué)積分均低于模型組(P＜0.01)。模型組血清總IgE、IL-4含量均高于正常對照組(P＜0.01)；各治療組均低于模型組(P＜0.01)；高、低劑量組與辛芩顆粒組比較，差異不明顯(P＞0.05)；中劑量組較辛芩顆粒組降低明顯(P＜0.05)；高、中、低劑量組與通竅鼻炎片組比較，差異無統(tǒng)計學(xué)意義(P＞0.05)。光鏡下，模型組大鼠鼻黏膜以大量炎細胞浸潤、水腫、充血，腺體增生為主，部分上皮組織脫落。各治療組鼻黏膜病理形態(tài)較模型組有顯著改善，以中劑量組對組織的修復(fù)作用突出。模型組AQP5平均光密度值(MOD)低于正常對照組(P＜0.05)；除辛芩顆粒組外，各治療組均高于模型組(P＜0.05)；高、中劑量組高于通竅鼻炎片組(P＜0.01)；低劑量組與通竅鼻炎片組比較，差異無統(tǒng)計學(xué)意義(P＞0.05)；高、中劑量組高于低劑量組(P＜0.01)；而高、中劑量組間比較，無統(tǒng)計學(xué)意義(P＞0.05)。結(jié)論：薯蕷丸加減方對AR大鼠療效顯著。降低血清IL-4含量，抑制IgE合成，減輕 免疫炎癥反應(yīng)，緩解鼻黏膜組織炎癥細胞浸潤，促進AQP5蛋白表達，調(diào)節(jié)鼻腔水液代謝，改善噴嚏、鼻癢、流涕等臨床癥狀，可能是該方對AR良好療效的作用機理之一。
[Abstract]:Aim: to establish the (AR) rat model of allergic rhinitis, to observe the effects of Dioscozhuang Pill on behavioral indexes, serum total IgE and IL-4 content, nasal mucosa pathological morphology and aquaporin 5 (AQP5) expression in AR rats, and to explore the mechanism of the prescription in the treatment of AR, so as to provide experimental theoretical basis for its better application in clinical practice. Methods: 70 SPF SD rats, male, were randomly divided into normal control group, model group, Xinqin granule group, Tongqiao rhinitis tablet group and Dioscorea zingiberensis pill addition and subtraction prescription group with 10 rats in each group. In addition to the normal control group, the AR rat model was established by ovalbumin (OVA) in each group. After the successful establishment of the model, the model group and the normal control group were given oral saline (1ml/ 0.1kg 路d). The high, middle and low dose groups were given Dioscorea Pill decoction (32, 16, 8 g / kg 路d), while the positive control group was given Xinqin granule (5g/ kg 路d), Tongqiao Biyan tablet (1.8g/ kg 路d). After 14 days of administration, abdominal aortic blood was taken from anesthetized rats, the total IgE,IL-4 content in serum was detected by enzyme-linked immunosorbent assay (ELISA), the nasal mucosa was removed and observed by HE staining, and the expression of AQP5 in nasal mucosa was detected by SABC method. Results: after modeling, the behavioral scores of each group were higher than those of the normal control group (P < 0.01), but there was no significant difference among the three groups (P > 0.05). After 14 days of intragastric administration, the behavioral scores of each treatment group were lower than those of the model group (P < 0.01). The content of serum total IgE,IL-4 in the model group was higher than that in the normal control group, and that in each treatment group was lower than that in the model group (P < 0.01). There was no significant difference between the high and low dose groups and Xinqin granule group (P > 0.05), but there was no significant difference between the high, middle and low dose groups and Tongqiao rhinitis tablet group (P > 0.05). Under light microscope, a large number of inflammatory cells infiltrated, edema, hyperemia, gland hyperplasia and partial epithelial tissue shedding in the nasal mucosa of the model group. The pathological morphology of nasal mucosa in each treatment group was significantly better than that in the model group, and the repair effect of the middle dose group on the tissue was more prominent. The mean optical density of AQP5 in the model group was lower than that in the normal control group (P < 0.05), except Xinqin granule group, all the treatment groups were higher than the model group (P < 0.05), the high and middle dose groups were higher than those in the Tongqiao rhinitis tablet group (P < 0.01), and there was no significant difference between the low dose group and the Tongqiao rhinitis tablet group (P > 0.05), and the high and middle dose groups were higher than the low dose group (P < 0.01). There was no significant difference between high and middle dose groups (P > 0.05). Conclusion: Dioscorea Pill is effective in AR rats. Reducing serum IL-4 content, inhibiting IgE synthesis, reducing immune inflammatory reaction, alleviating inflammatory cell infiltration in nasal mucosa, promoting AQP5 protein expression, regulating nasal water metabolism, improving sneezing, nasal itching, runny nose and other clinical symptoms may be one of the good therapeutic effects of this prescription on AR.
【學(xué)位授予單位】：云南中醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R276.1
[Abstract]:Aim: to establish the (AR) rat model of allergic rhinitis, to observe the effects of Dioscozhuang Pill on behavioral indexes, serum total IgE and IL-4 content, nasal mucosa pathological morphology and aquaporin 5 (AQP5) expression in AR rats, and to explore the mechanism of the prescription in the treatment of AR, so as to provide experimental theoretical basis for its better application in clinical practice. Methods: 70 SPF SD rats, male, were randomly divided into normal control group, model group, Xinqin granule group, Tongqiao rhinitis tablet group and Dioscorea zingiberensis pill addition and subtraction prescription group with 10 rats in each group. In addition to the normal control group, the AR rat model was established by ovalbumin (OVA) in each group. After the successful establishment of the model, the model group and the normal control group were given oral saline (1ml/ 0.1kg 路d). The high, middle and low dose groups were given Dioscorea Pill decoction (32, 16, 8 g / kg 路d), while the positive control group was given Xinqin granule (5g/ kg 路d), Tongqiao Biyan tablet (1.8g/ kg 路d). After 14 days of administration, abdominal aortic blood was taken from anesthetized rats, the total IgE,IL-4 content in serum was detected by enzyme-linked immunosorbent assay (ELISA), the nasal mucosa was removed and observed by HE staining, and the expression of AQP5 in nasal mucosa was detected by SABC method. Results: after modeling, the behavioral scores of each group were higher than those of the normal control group (P < 0.01), but there was no significant difference among the three groups (P > 0.05). After 14 days of intragastric administration, the behavioral scores of each treatment group were lower than those of the model group (P < 0.01). The content of serum total IgE,IL-4 in the model group was higher than that in the normal control group, and that in each treatment group was lower than that in the model group (P < 0.01). There was no significant difference between the high and low dose groups and Xinqin granule group (P > 0.05), but there was no significant difference between the high, middle and low dose groups and Tongqiao rhinitis tablet group (P > 0.05). Under light microscope, a large number of inflammatory cells infiltrated, edema, hyperemia, gland hyperplasia and partial epithelial tissue shedding in the nasal mucosa of the model group. The pathological morphology of nasal mucosa in each treatment group was significantly better than that in the model group, and the repair effect of the middle dose group on the tissue was more prominent. The mean optical density of AQP5 in the model group was lower than that in the normal control group (P < 0.05), except Xinqin granule group, all the treatment groups were higher than the model group (P < 0.05), the high and middle dose groups were higher than those in the Tongqiao rhinitis tablet group (P < 0.01), and there was no significant difference between the low dose group and the Tongqiao rhinitis tablet group (P > 0.05), and the high and middle dose groups were higher than the low dose group (P < 0.01). There was no significant difference between high and middle dose groups (P > 0.05). Conclusion: Dioscorea Pill is effective in AR rats. Reducing serum IL-4 content, inhibiting IgE synthesis, reducing immune inflammatory reaction, alleviating inflammatory cell infiltration in nasal mucosa, promoting AQP5 protein expression, regulating nasal water metabolism, improving sneezing, nasal itching, runny nose and other clinical symptoms may be one of the good therapeutic effects of this prescription on AR.
【學(xué)位授予單位】：云南中醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R276.1
【參考文獻】
相關(guān)期刊論文 前10條
1 張羅,周兵,韓德民,顧之燕;變應(yīng)性鼻炎研究進展(一):發(fā)病機制[J];耳鼻咽喉頭頸外科;2003年05期
2 張羅;顧之燕;鄭銘;韓德民;;過敏性鼻炎患病狀況研究[J];中國耳鼻咽喉頭頸外科;2009年11期
3 高學(xué)清,雷福云;薯蕷糖漿防治小兒反復(fù)呼吸道感染39例[J];國醫(yī)論壇;2001年02期
4 崔秀麗;許振林;;頑固性皮膚瘙癢從脾論治驗案3則[J];中醫(yī)藥臨床雜志;2009年04期
5 李壽v
本文編號：2503599
本文鏈接：http://sikaile.net/yixuelunwen/mazuiyixuelunwen/2503599.html
最近更新
教材專著
